Table 2.
Comparison of the examined parameters between parotid and submandibular glands of the control and streptozotocin-diabetic rats.
| Group N = 8 | PG | SMG |
p
PG : SMG |
|---|---|---|---|
| Salivary glands weight (g) M (min–max) | |||
| C1 | 0.09 (0.08–0.12) | 0.19 (0.18–0.22) | ns |
| C2 | 0.09 (0.79–0.13) | 0.21 (0.17–0.24) | ns |
| DM1 | 0.09 (0.07–0.09) | 0.21 (0.14–0.24) | ns |
| DM2 | 0.07 (0.06–0.09) | 0.18 (0.11–0.19) | ns |
|
| |||
| TAS (μmol/mg of protein) M (min–max) | |||
| C1 | 2.84 (2.01–3.81) | 1.94 (1.75–2.06) | <0.005 (↑) |
| C2 | 2.69 (2.15–2.99) | 1.89 (1.84–2.10) | <0.005 (↑) |
| DM1 | 2.36 (2.30–2.89) | 2.16 (2.10–2.30) | <0.05 (↑) |
| DM2 | 1.40 (0.42–1.74) | 1.76 (1.17–1.82) | ns |
|
| |||
| TOS (μmol/mg of protein) M (min–max) | |||
| C1 | 0.04 (0.02–0.21) | 0.014 (0.01–0.11) | <0.0005 (↑) |
| C2 | 0.042 (0.02–0.26) | 0.02 (0.01–0.30) | <0.005 (↑) |
| DM1 | 0.057 (0.05–0.08) | 0.02 (0.018–0.021) | <0.0005 (↑) |
| DM2 | 0.067 (0.01–0.09) | 0.03 (0.008–0.04) | <0.005 (↑) |
|
| |||
| OSI M (min–max) | |||
| C1 | 14.08 (6.32–17.52) | 7.22 (7.17–12.17) | ns |
| C2 | 15.61 (5.21–22.5) | 10.58 (4.97–19.35) | ns |
| DM1 | 24.15 (19.97–39.81) | 9.26 (6.67–12.54) | <0.0005 (↑) |
| DM2 | 47.86 (36.52–59.86) | 17.05 (6.02–25.33) | <0.0005 (↑) |
|
| |||
| PC (nmol/mg of protein) M (min–max) | |||
| C1 | 0.051 (0.025–0.10) | 0.051 (0.019–0.065) | ns |
| C2 | 0.055 (0.019–0.100) | 0.049 (0.016–0.070) | ns |
| DM1 | 0.061 (0.058–0.084) | 0.056 (0.036–0.064) | <0.05 (↑) |
| DM2 | 0.068 (0.039–0.127) | 0.061 (0.040–0.136) | <0.05 (↑) |
|
| |||
| 4-HNE protein adduct (μg/mg of protein) M (min–max) | |||
| C1 | 0.32 (0.24–0.38) | 0.30 (0.28–0.34) | ns |
| C2 | 0.34 (0.30–0.39) | 0.36 (0.33–0.37) | ns |
| DM1 | 0.46 (0.43–0.57) | 0.39 (0.26–0.41) | <0.05 (↑) |
| DM2 | 0.65 (0.57–0.74) | 0.45 (0.39–0.54) | <0.005 (↑) |
|
| |||
| oxy-LDL/MDA (ng/mg of protein) M (min–max) | |||
| C1 | 0.31 (0.26–0.33) | 0.28 (0.25–0.29) | ns |
| C2 | 0.31 (0.22–0.32) | 0.29 (0.27–0.32) | ns |
| DM1 | 0.37 (0.35–0.49) | 0.32 (0.28–0.4) | <0.05 (↑) |
| DM2 | 0.38 (0.35–0.53) | 0.33 (0.32–0.38) | <0.05 (↑) |
|
| |||
| 8-isoP (pg/mg of protein) M (min–max) | |||
| C1 | 0.022 (0.019–0.029) | 0.022 (0.019–0.033) | ns |
| C2 | 0.020 (0.015–0.021) | 0.019 (0.014–0.025) | ns |
| DM1 | 0.023 (0.021–0.057) | 0.019 (0.011–0.021) | <0.05 (↑) |
| DM2 | 0.028 (0.021–0.044) | 0.023 (0.019–0.028) | <0.05 (↑) |
|
| |||
| 8-OHdG (pg/mg of protein) M (min–max) | |||
| C1 | 0.64 (0.30–1.40) | 0.57 (0.51–0.61) | ns |
| C2 | 0.70 (0.41–2.00) | 0.54 (0.49–0.68) | ns |
| DM1 | 0.53 (0.31–0.63) | 0.52 (0.32–0.63) | ns |
| DM2 | 0.91 (0.74–1.65) | 0.51 (0.41–0.97) | <0.005 (↑) |
C1: control group in the first week of the experiment, C2: control group in the second week of the experiment, DM1: diabetic group in the first week of the experiment, DM2: diabetic group in the first second of the experiment, PG: parotid gland, SMG: submandibular gland, TAS: total antioxidant status, TOS: total oxidant status, OSI: oxidative status index, PC: protein carbonyls, 4-HNE protein adduct: 4-hydroxynonenal protein adduct, oxy-LDL/MDA: oxidized and/or MDA-modified LDL-cholesterol, 8-isoP: 8-isoprostanes, 8-OHdG: 8-hydroxy-D-guanosine, ns: not significant, p: statistical significance < 0.05, M: median, min: minimum, max: maximum, and (↑): increase.